Rationale: Economic evaluations of pharmaceuticals require that health outcomes include adverse as well as beneficial effects of therapy. When the incidence and/or severity of adverse drug reactions (ADRs) result in an unfavourable risk/benefit profile, regulatory authorities such as the EMEA...

Background: Compared with conventional top down costing, micro-costing may provide a more accurate method of resource-use assessment in economic analyses of surgical interventions, but little is known about its current use. The aim of this study was to systematically-review the use of...